PUBLIC COMPANY
save$CORTCORCEPT THERAPEUTICS INC
$CORT116.23+1.93%Redwood City, CA, USupdated 1d ago
Corcept Therapeutics Inc. is a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders. Corcept has focused on the adverse effects of excess cortisol, studying new compounds that may mitigate those effects. Its executive team is headed by CEO, president and director Joseph K. Belanoff, MD.
community read0 votes
pipeline
2
marketed
2
phase 3
0
catalysts ytd
4
approvals ytd
1
recalls ytd
0
Pipeline(2)
pipeline depth2 products
2Marketed
Upcoming
no upcoming catalysts on record
Recent(90d)
earnings (2)
Active trials
- phase2A Phase 2b, Study Evaluating Miricorilant in Adult Patients With Nonalcoholic Steatohepatitis/Metabolic Dysfunction-Associated Steatohepatitis (MONARCH)
- phase3Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer
- phase2Two Part Study of Nenocorilant Combined With Nivolumab in Patients With Advanced Solid Malignancies
- phase2Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers
- phase2Relacorilant With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma
- phase1Evaluating the Pharmacokinetics and Safety of Miricorilant
- phase2Extension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Cushing Syndrome
- phase1Study Evaluating the Bioavailability of Miricorilant With Optional Food Effect Assessment in Healthy Adult Subjects
Insider activity
source: SEC Form 4routine RSU / option mechanics (1)
- Apr 22, 26giftWILSON JAMES N · director2,000 sh
🐶 Hiring Signal
News
- Axoltis misses the mark in phase 2 ALS study, but will persevere with the synthetic peptideAxoltis Pharma's phase 2 trial for amyotrophic lateral sclerosis may have missed its primary endpoint, but the French biotech has pointed to secondary endpoints to justify persevering with the synt…fiercebiotech · 20d ago
- Pfizer CFO to depart; GSK wins approval for UTI drugPlus news about Apellis Pharmaceuticals, Servier, TORL BioTherapeutics, Verastem, Corcept Therapeutics, Legend Biotech, COUR Pharmaceuticals, cAMPfield Therapeutics and LabGenius Therapeutics. 👋 P…endpoints · 3mo ago
- Giants of Cancer Care Announces the 14th Annual Class of Inducteesonclive · 4mo ago
Data sources
last refreshed 27m ago
Found something off?
comments(0)
5-min edit window · permanent after that